Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 4, 2008, Pages 607-614

  McColl, S L ^a   Burstein, A H ^b   Reeves, K R ^b   Billing Jr , C B ^b   Stolar, M ^b   Sellers, E M ^a,c,d  

^a DecisionLine Clinical Research Corporation   (Canada)

^b PFIZER INC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; VARENICLINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; MEDICAL LIABILITY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; XEROSTOMIA;

ADULT; AMPHETAMINE; BENZAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NICOTINIC AGONISTS; ODDS RATIO; QUESTIONNAIRES; QUINOXALINES; REPRODUCIBILITY OF RESULTS; SMOKING; SMOKING CESSATION; SUBSTANCE-RELATED DISORDERS;

EID: 40949151210     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100510     Document Type: Article

References (39)

1. Shoaib, M., Schindler, C.W. & Goldberg, S.R. Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology (Berl) 129, 35-43 (1997).
2. Mansvelder, H.D., Keath, J.R. & McGehee, D.S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33, 905-919 (2002).
3. Corrigall, W.A. & Coen, K.M. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 99, 473-478 (1989).
4. Benowitz, N.L. Pharmacology of nicotine: addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 36, 597-613 (1996).
5. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. The Health Consequences of Smoking: Nicotine Addiction, A Report of the Surgeon General: Rockville, MD,1988 〈http://www. surgeongeneral.gov/library/reports.htm〉.
6. Henningfield, J.E. & Goldberg, S.R. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol. Biochem. Behav. 19, 989-992 (1983).
7. Henningfield, J.E., Miyasato, K. & Jasinski, D.R. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J. Pharmacol. Exp. Ther. 234, 1-12 (1985).
8. Stitzer, M.L. & de Wit, H. Abuse liability of nicotine. In Nicotine Safety and Toxicity. (ed. Benowitz, N.L.) 119-131 (Oxford Univ. Press, New York, 1998).
9. Schuh, K.J., Schuh, L.M., Henningfield, J.E. & Stitzer, M.L. Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology (Berl) 130, 352-361 (1997).
10. West, R., Hajek, P., Foulds, J., Nilsson, F., May, S. & Meadows, A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl). 149, 198-202 (2000).
11. Houtsmuller, E.J., Henningfield, J.E. & Stitzer, M.L. Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology (Berl) 167, 20-27 (2003).
12. Tonstad, S. et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296, 64-71 (2006).
13. Nides, M. et al. Smoking cessation with varenicline, a selective alpha-4 beta-2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch. Intern. Med. 166, 1561-1568 (2006).
14. Oncken, C. et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med. 166, 1571-1577 (2006).
15. Williams, K.E., Reeves, K., Billing, C.B., Pennington, A.M. & Gong, J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr. Med. Res. Opin. 23, 793 (2007).
16. Jorenby, D.E. et al. Efficacy of varenicline, an ?4?2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296, 56-63 (2006).
17. Gonzales, D. et al. Varenicline, an ?4?2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296, 47-55 (2006).
18. Coe, J.W. et al. Varenicline: an ?4?2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48, 3474-3477 (2005).
19. Rollema, H. et al. Pharmacological profile of the ?4?2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52, 985-994 (2007).
20. Jasinski, D.R., Pevnick, J.S. & Griffith, J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch. Gen. Psychiatry 35, 501-516 (1978).
21. Jasinski, D.R. & Preston, K.L. Assessment of dezocine for morphine-like subjective effects and miosis. Clin. Pharmacol. Ther. 38, 544-548 (1985).
22. Busto, U., Kaplan, H.L., Zawertailo, L. & Sellers, E.M. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clin. Pharmacol. Ther. 55, 451-463 (1994).
23. Faessel, H.M., Smith, B.J., Gibbs, M.A., Gobey, J.S., Clark, D.J. & Burstein, A.H. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J. Clin. Pharmacol. 46, 991-998 (2006).
24. Balster, R.L. & Bigelow, G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 70, S13-S40 (2003).
25. Mumford, G.K., Evans, S.M., Fleishaker, J.C. & Griffiths, R.R. Alprazolam absorption kinetics affects abuse liability. Clin. Pharmacol. Ther. 57, 356-365 (1995).
26. O'Brien, C.P. Drug addiction and drug abuse. In The Pharmacological Basis of Therapeutics 10th edn., (eds. Hardman, J.G., Limbird, L.E. & Goodman-Gilman, A.) 621-642 (McGraw-Hill, New York, 2001).
27. Smith, B.J., Jones, H.E. & Griffiths, R.R. Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. Psychopharmacology (Berl). 156, 435-444 (2001).
28. Schuh, L.M., Schuster, C.R., Hopper, J.A. & Mendel, C.M. Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology (Berl) 147, 339-346 (2000).
29. Griffith, J.D., Carranza, J., Griffith, C. & Miller, L.L. Bupropion: clinical assay for amphetamine-like abuse potential. J. Clin. Psychiatry 44, 206-208 (1983).
30. Miller, L. & Griffith, J. A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology (Berl) 80, 199-205 (1983).
31. Houtsmuller, E.J., Fant, R.V., Eissenberg, T.E., Henningfield, J.E. & Stitzer, M.L. Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol. Biochem. Behav. 72, 559-568 (2002).
32. Fagerström, K.O. & Schneider, N.G. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J. Behav. Med. 12, 159-182 (1989).
33. Busto, U.E., Zawertailo, L.A., Kaplan, H.L. & Sellers, E.M. Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing. Can. J. Clin. Pharmacol. 6, 103-110 (1999).
34. McColl, S.L., Schoedel, K., Romach, M.K. & Sellers, E.M. Improving signal detection in human abuse liability studies: a case for using prestudy pharmacological testing. Abstract from the Annual Meeting of the College of Problem Drug Dependence 519, 131 (2006).
35. McColl, S. & Sellers, E.M. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend. 83(Suppl. 1), S52-S62 (2006).
36. Griffiths, R.R., Bigelow, G.E. & Ator, N.A. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 70, S41-S54 (2003).
37. Preston, K.L. & Walsh, S.L. Evaluating abuse liability: methods and predictive value. In Drug Abuse Handbook (ed. Karch, S.B.) 276-306 (CRC Press, Boca Raton, LA, 1998).
38. Martin, W.R., Sloan, J.W., Sapira, J.D. & Jasinski, D.R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 12, 245-258 (1971).
39. Cole, J.O., Orzack, M.H., Beake, B., Bird, M. & Bar-Tal, Y. Assessment of the abuse liability of buspirone in recreational sedative users. J. Clin. Psychiatry 43, 69-75 (1982).